AIM: To obtain human recombinant Fv-immunotoxin hscFv(25)-mTNFalpha (mutant human TNFalpha fused to human scFv(25)) against hepatocellular carcinoma (HCC). METHODS: Two relevant sites of enzymatic digestion were added to mTNFalpha by PCR. MTNFalpha was linked to the 3' end of hscFv(25) in pGEX4T-1 vector. This anti-HCC recombinant Fv-immunotoxin hscFv(25)-mTNFalpha was expressed in Escherichia coli and purified from inclusions. After purified by glutathione-S-transferase affinity chromatography and thrombin digestion, it was identified by electrophoresis and Western blot. And then, the purified recombinant Fv-immunotoxin was injected into nude mice with HCC xenografts through their tail veins. MTNFalpha protein and PBS were used as control at the same time. After treated for two weeks, nude mice were executed. The bulk and weight of tumors were observed. The tumor tissues were stained by immunohistochemical method with TNFalpha antibody. RESULTS: The expression ratio of recombinant Fv-immunotoxin hscFv(25)-mTNFalpha was 12% of bacterial protein. The result of tumor restraining trials of hscFv(25)-mTNFalpha showed 2/5 complete remission and 3/5 partial remission. mTNFalpha restraining trials showed 5/5 partial remission. The therapeutic result of hscFv(25)-mTNFalpha was better than that of mTNFalpha (F=8.70, P<0.05). The hscFv(25)-mTNFalpha remedial tumor tissues were positive for TNFalpha by immunohistochemical staining. The positive granules mainly existed in the cytoplasm of tumor cell. CONCLUSION: Recombinant Fv-immunotoxin hscFv(25)-mTNFalpha has better therapeutic effect than mTNFalpha. It can inhibit the cellular growth of HCC and has some potential of clinical application.
AIM: To obtain human recombinant Fv-immunotoxin hscFv(25)-mTNFalpha (mutant humanTNFalpha fused to human scFv(25)) against hepatocellular carcinoma (HCC). METHODS: Two relevant sites of enzymatic digestion were added to mTNFalpha by PCR. MTNFalpha was linked to the 3' end of hscFv(25) in pGEX4T-1 vector. This anti-HCC recombinant Fv-immunotoxin hscFv(25)-mTNFalpha was expressed in Escherichia coli and purified from inclusions. After purified by glutathione-S-transferase affinity chromatography and thrombin digestion, it was identified by electrophoresis and Western blot. And then, the purified recombinant Fv-immunotoxin was injected into nude mice with HCC xenografts through their tail veins. MTNFalpha protein and PBS were used as control at the same time. After treated for two weeks, nude mice were executed. The bulk and weight of tumors were observed. The tumor tissues were stained by immunohistochemical method with TNFalpha antibody. RESULTS: The expression ratio of recombinant Fv-immunotoxin hscFv(25)-mTNFalpha was 12% of bacterial protein. The result of tumor restraining trials of hscFv(25)-mTNFalpha showed 2/5 complete remission and 3/5 partial remission. mTNFalpha restraining trials showed 5/5 partial remission. The therapeutic result of hscFv(25)-mTNFalpha was better than that of mTNFalpha (F=8.70, P<0.05). The hscFv(25)-mTNFalpha remedial tumor tissues were positive for TNFalpha by immunohistochemical staining. The positive granules mainly existed in the cytoplasm of tumor cell. CONCLUSION: Recombinant Fv-immunotoxin hscFv(25)-mTNFalpha has better therapeutic effect than mTNFalpha. It can inhibit the cellular growth of HCC and has some potential of clinical application.
Authors: Stephen P Cooke; R Barbara Pedley; R Boden; Richard H J Begent; Kerry A Chester Journal: Bioconjug Chem Date: 2002 Jan-Feb Impact factor: 4.774
Authors: F Turatti; D Mezzanzanica; E Nardini; E Luison; L Maffioli; E Bambardieri; C de Lalla; S Canevari; M Figini Journal: Cancer Immunol Immunother Date: 2001-02 Impact factor: 6.968
Authors: A Mayer; E Tsiompanou; D O'Malley; G M Boxer; J Bhatia; A A Flynn; K A Chester; B R Davidson; A A Lewis; M C Winslet; A P Dhillon; A J Hilson; R H Begent Journal: Clin Cancer Res Date: 2000-05 Impact factor: 12.531
Authors: A M McCall; L Shahied; A R Amoroso; E M Horak; H H Simmons; U Nielson; G P Adams; R Schier; J D Marks; L M Weiner Journal: J Immunol Date: 2001-05-15 Impact factor: 5.422
Authors: H G van der Poel; B Molenaar; V W van Beusechem; H J Haisma; R Rodriguez; D T Curiel; W R Gerritsen Journal: J Urol Date: 2002-07 Impact factor: 7.450
Authors: Dominic Fan; Seiji Yano; Hisashi Shinohara; Carmen Solorzano; Melissa Van Arsdall; Corazon D Bucana; Sen Pathak; Ewa Kruzel; Roy S Herbst; Amir Onn; Jennifer S Roach; Masanori Onda; Qing-cheng Wang; Ira Pastan; Isaiah J Fidler Journal: Mol Cancer Ther Date: 2002-06 Impact factor: 6.009
Authors: K A Chester; J Bhatia; G Boxer; S P Cooke; A A Flynn; A Huhalov; A Mayer; R B Pedley; L Robson; S K Sharma; D I Spencer; R H Begent Journal: Dis Markers Date: 2000 Impact factor: 3.434